Loss of PKR activity in chronic lymphocytic leukemia.

PubWeight™: 0.99‹?› | Rank: Top 15%

🔗 View Article (PMID 14961569)

Published in Int J Cancer on April 10, 2004

Authors

Su Ing Hii1, Lani Hardy, Tania Crough, Elizabeth J Payne, Karen Grimmett, Devinder Gill, Nigel A J McMillan

Author Affiliations

1: Cancer Biology Programme, Centre for Immunology and Cancer Research, University of Queensland, Brisbane, Australia.

Articles citing this

Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol Mol Biol Rev (2006) 4.13

NSs protein of rift valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase. J Virol (2009) 2.39

Cell death/proliferation roles for nc886, a non-coding RNA, in the protein kinase R pathway in cholangiocarcinoma. Oncogene (2012) 1.03

PKR regulates B56(alpha)-mediated BCL2 phosphatase activity in acute lymphoblastic leukemia-derived REH cells. J Biol Chem (2008) 0.93

Prognostic significance of RNA-dependent protein kinase on non-small cell lung cancer patients. Clin Cancer Res (2010) 0.91

PKR regulates proliferation, differentiation, and survival of murine hematopoietic stem/progenitor cells. Blood (2013) 0.90

The role of PKR/eIF2α signaling pathway in prognosis of non-small cell lung cancer. PLoS One (2011) 0.85

PKR negatively regulates leukemia progression in association with PP2A activation, Bcl-2 inhibition and increased apoptosis. Blood Cancer J (2013) 0.84

Implication of protein kinase R gene quantification in hepatitis C virus genotype 4 induced hepatocarcinogenesis. Diagn Pathol (2012) 0.83

Increased expression of the dsRNA-activated protein kinase PKR in breast cancer promotes sensitivity to doxorubicin. PLoS One (2012) 0.81

RNA-dependent protein kinase (PKR) depletes nutrients, inducing phosphorylation of AMP-activated kinase in lung cancer. Oncotarget (2015) 0.80

Prognostic significance of combinations of RNA-dependent protein kinase and EphA2 biomarkers for NSCLC. J Thorac Oncol (2013) 0.77

Articles by these authors

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol (2006) 8.53

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med (2014) 6.73

Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol (2003) 1.80

Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clin Chim Acta (2006) 1.66

Practical considerations for the measurement of free light chains in serum. Clin Chem (2003) 1.56

Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity. Leuk Lymphoma (2012) 1.43

Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood (2006) 1.41

Lipidic systems for in vivo siRNA delivery. AAPS J (2009) 1.33

Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma. Clin Cancer Res (2012) 1.26

MicroRNAs regulate tumor angiogenesis modulated by endothelial progenitor cells. Cancer Res (2012) 1.21

Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clin Cancer Res (2006) 1.19

Significance of abnormal protein bands in patients with multiple myeloma following autologous stem cell transplantation. Clin Biochem Rev (2009) 1.15

Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. Br J Haematol (2002) 1.14

Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood (2007) 1.12

Papillomavirus virus-like particles activate the PI3-kinase pathway via alpha-6 beta-4 integrin upon binding. Virology (2006) 1.10

CCL2 and CXCL2 enhance survival of primary chronic lymphocytic leukemia cells in vitro. Leuk Lymphoma (2012) 1.09

Human papillomavirus DNA detected in peripheral blood samples from healthy Australian male blood donors. J Med Virol (2009) 1.07

High prevalence of human papillomaviruses in fresh frozen breast cancer samples. J Med Virol (2011) 1.06

RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. Mol Pharmacol (2005) 1.03

Cross-reactive recognition of human and primate cytomegalovirus sequences by human CD4 cytotoxic T lymphocytes specific for glycoprotein B and H. Eur J Immunol (2004) 1.02

Rational design of immunostimulatory siRNAs. Mol Ther (2010) 1.02

A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood (2004) 0.98

Both treated and untreated tumors are eliminated by short hairpin RNA-based induction of target-specific immune responses. Proc Natl Acad Sci U S A (2009) 0.95

Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV® assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications. PLoS One (2013) 0.95

Development of a novel method for formulating stable siRNA-loaded lipid particles for in vivo use. Pharm Res (2008) 0.94

Phosphorylation of HIV Tat by PKR increases interaction with TAR RNA and enhances transcription. Virol J (2005) 0.92

RNA interference for the treatment of cancer. Drug News Perspect (2006) 0.92

Tumor-specific but not nonspecific cell-free circulating DNA can be used to monitor disease response in lymphoma. Am J Hematol (2011) 0.92

Human papillomavirus type spectrum in normal skin of individuals with or without a history of frequent sun exposure. J Gen Virol (2008) 0.91

The human papillomavirus type 16 E7 protein binds human interferon regulatory factor-9 via a novel PEST domain required for transformation. J Interferon Cytokine Res (2006) 0.91

Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen. Cancer Immunol Immunother (2002) 0.91

Human papillomavirus in benign prostatic hyperplasia and prostatic adenocarcinoma patients. Pathol Oncol Res (2011) 0.91

siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo. Immunol Cell Biol (2011) 0.90

Retracted Dendrimer nanocarriers as versatile vectors in gene delivery. Nanomedicine (2009) 0.89

Vaginal delivery of siRNA using a novel PEGylated lipoplex-entrapped alginate scaffold system. J Control Release (2011) 0.88

A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse. Leuk Lymphoma (2008) 0.88

Granulocyte-colony stimulating factor increases CD123hi blood dendritic cells with altered CD62L and CCR7 expression. Blood (2002) 0.88

Determining virological, serological and immunological parameters of EBV infection in the development of PTLD. Int Immunol (2004) 0.88

Narrowing of T-cell receptor beta variable repertoire during symptomatic herpesvirus infection in transplant patients. Immunol Cell Biol (2009) 0.87

Papillomavirus in healthy skin of Australian animals. J Gen Virol (2006) 0.87

Molecular basis of pathogenesis, prognosis and therapy in chronic lymphocytic leukaemia. Cancer Biol Ther (2007) 0.86

CD62L as a therapeutic target in chronic lymphocytic leukemia. Clin Cancer Res (2013) 0.86

Neutrophil dysplasia characterised by a pseudo-Pelger-Huet anomaly occurring with the use of mycophenolate mofetil and ganciclovir following renal transplantation: a report of five cases. Pathology (2002) 0.84

Induction with oral chemotherapy (CID) followed by early autologous stem cell transplantation for de novo multiple myeloma patients. Hematol J (2004) 0.84

Plasma protein C levels in immunocompromised septic patients are significantly lower than immunocompetent septic patients: a prospective cohort study. J Hematol Oncol (2009) 0.83

Ex vivo expansion of human cytomegalovirus-specific cytotoxic T cells by recombinant polyepitope: implications for HCMV immunotherapy. Eur J Immunol (2005) 0.83

Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation. Blood (2009) 0.83

MRI features of bone marrow necrosis. AJR Am J Roentgenol (2007) 0.82

IL-10 mediates suppression of the CD8 T cell IFN-gamma response to a novel viral epitope in a primed host. J Immunol (2003) 0.82

Self-adjuvanting polymer-peptide conjugates as therapeutic vaccine candidates against cervical cancer. Biomacromolecules (2013) 0.82

The reporting of serum protein electrophoresis to clinicians. Clin Chim Acta (2005) 0.81

Outcome of treatment of adult acute lymphoblastic leukemia with hyperfractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone/methotrexate, cytarabine: results from an Australian population. Leuk Lymphoma (2010) 0.81

Prognostic value of ZAP-70 expression in chronic lymphocytic leukemia as assessed by quantitative polymerase chain reaction and flow cytometry. Cytometry B Clin Cytom (2014) 0.81

Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy. Leuk Lymphoma (2006) 0.81

The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization. Hematol Oncol (2006) 0.80

CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy. Am J Hematol (2013) 0.80

Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma. Leuk Lymphoma (2010) 0.80

Self-catalyzed degradable cationic polymer for release of DNA. Biomacromolecules (2011) 0.79

WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation. Leuk Res (2011) 0.79

Role of VAD in the initial treatment of multiple myeloma. Blood (2005) 0.79

Self-catalyzed degradation of linear cationic poly(2-dimethylaminoethyl acrylate) in water. Biomacromolecules (2011) 0.79

Immunoselection of functional CMRF-56+ blood dendritic cells from multiple myeloma patients for immunotherapy. J Immunother (2005) 0.78

RNA interference for viral infections. Curr Drug Targets (2012) 0.78

A single-centre experience of post-renal transplant lymphoproliferative disorder. Transpl Int (2003) 0.77

The development and future of oligonucleotide-based therapies for cervical cancer. Curr Opin Mol Ther (2007) 0.77

Effective Delivery of PEGylated siRNA-Containing Lipoplexes to Extraperitoneal Tumours following Intraperitoneal Administration. J Drug Deliv (2011) 0.77

Potent inhibition of Hendra virus infection via RNA interference and poly I:C immune activation. PLoS One (2013) 0.77

Dendrosome-based delivery of siRNA against E6 and E7 oncogenes in cervical cancer. Nanomedicine (2010) 0.76

A novel method for screening viral interferon-resistance genes. J Interferon Cytokine Res (2004) 0.76

Polyacrylate-based delivery system for self-adjuvanting anticancer peptide vaccine. J Med Chem (2014) 0.76

Multiple signal pathways in the leukemogenesis and therapeutic implications. Leuk Res (2007) 0.75

Selective accumulation of virus-specific CD8+ T cells within the peripheral blood stem cell compartment. Blood (2009) 0.75

Self-adjuvanting therapeutic peptide-based vaccine induce CD8+ cytotoxic T lymphocyte responses in a murine human papillomavirus tumor model. Curr Drug Deliv (2015) 0.75

Identification of tumours with the CD43 only phenotype during the investigation of suspected lymphoma: a heterogeneous group not necessarily of T cell origin. Pathology (2002) 0.75

Treatment of acute promyelocytic leukaemia in the Jehovah's Witness population. Ann Hematol (2010) 0.75

B cell chronic lymphocytic leukaemia cells have reduced capacity to upregulate expression of MHC class I in response to interferon-gamma. Pathology (2004) 0.75

Epstein-Barr virus T-cell immunity despite rituximab. Br J Haematol (2007) 0.75

Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia. Leuk Lymphoma (2014) 0.75

Methotrexate-associated mantle-cell lymphoma in an elderly man with myasthenia gravis. Nat Clin Pract Oncol (2008) 0.75